IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
37.02
+0.78 (2.15%)
Aug 7, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 272.59 | 112.83 | 84.38 | 157.02 | 68.63 | 92.05 |
Short-Term Investments | 556.37 | 526.56 | 591.94 | 368.1 | 296.2 | 154.72 |
Cash & Short-Term Investments | 828.96 | 639.39 | 676.32 | 525.11 | 364.83 | 246.77 |
Cash Growth | 23.77% | -5.46% | 28.79% | 43.93% | 47.84% | -12.98% |
Accounts Receivable | - | - | - | 0.02 | 0.21 | 1.1 |
Other Current Assets | 35.07 | 27.34 | 13.39 | 7.5 | 5.41 | 3.12 |
Total Current Assets | 864.03 | 666.73 | 689.71 | 532.63 | 370.45 | 251 |
Net Property, Plant & Equipment | 30.46 | 31.29 | 27.74 | 8.41 | 8.99 | 8.66 |
Long-Term Investments | 413.93 | 410.3 | 405.83 | 107.49 | 8.32 | 121.29 |
Other Long-Term Assets | 1.28 | 1.02 | 0.81 | 0.78 | 0.21 | 0.4 |
Total Assets | 1,310 | 1,109 | 1,124 | 649.32 | 387.97 | 381.35 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 30.51 | 17.58 | 15.42 | 6.6 | 4.28 | 2.1 |
Accrued Expenses | 50.98 | 40.89 | 30.35 | 18.76 | 17 | 12.32 |
Current Portion of Leases | 1.19 | 0.34 | 0.3 | 1.75 | 1.87 | 1.7 |
Unearned Revenue | - | - | - | - | 8.57 | 29.04 |
Total Current Liabilities | 82.68 | 58.82 | 46.07 | 27.1 | 31.72 | 45.16 |
Long-Term Leases | 28.12 | 27.58 | 18.87 | 1.13 | 1.61 | 3.48 |
Other Long-Term Liabilities | - | - | - | - | 5.19 | 31.19 |
Total Long-Term Liabilities | 28.12 | 27.58 | 18.87 | 1.13 | 6.8 | 34.67 |
Total Liabilities | 110.79 | 86.39 | 64.94 | 28.23 | 38.51 | 79.83 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Additional Paid-in Capital | 2,148 | 1,757 | 1,681 | 968.89 | 587.72 | 478.97 |
Accumulated Other Comprehensive Income | -1.67 | 2.27 | 0.81 | 0.56 | -2.87 | -0.71 |
Retained Earnings | -947.53 | -736.54 | -622.84 | -348.36 | -235.4 | -176.75 |
Shareholders' Equity | 1,199 | 1,023 | 1,059 | 621.09 | 349.46 | 301.51 |
Total Liabilities & Equity | 1,310 | 1,109 | 1,124 | 649.32 | 387.97 | 381.35 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 29.31 | 27.91 | 19.17 | 2.87 | 3.48 | 5.18 |
Net Cash (Debt) | 799.65 | 611.47 | 657.15 | 522.24 | 361.35 | 241.59 |
Net Cash Growth | 24.34% | -6.95% | 25.83% | 44.53% | 49.57% | -12.74% |
Net Cash Per Share | 8.91 | 6.91 | 8.05 | 9.08 | 8.72 | 6.85 |
Book Value | 1,199 | 1,023 | 1,059 | 621.09 | 349.46 | 301.51 |
Book Value Per Share | 13.36 | 11.56 | 12.97 | 10.80 | 8.43 | 8.55 |
Tangible Book Value | 1,199 | 1,023 | 1,059 | 621.09 | 349.46 | 301.51 |
Tangible Book Value Per Share | 13.36 | 11.56 | 12.97 | 10.80 | 8.43 | 8.55 |